| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 334 | 2023 | 35425 | 4.140 |
Why?
|
| Cerebrovascular Circulation | 73 | 2022 | 2732 | 2.900 |
Why?
|
| Brain Mapping | 104 | 2022 | 6670 | 2.810 |
Why?
|
| Brain | 162 | 2023 | 26388 | 2.530 |
Why?
|
| Positron-Emission Tomography | 38 | 2023 | 6234 | 2.010 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 20 | 2022 | 2737 | 1.770 |
Why?
|
| Magnetic Resonance Spectroscopy | 61 | 2021 | 3759 | 1.480 |
Why?
|
| Blood Volume | 31 | 2012 | 565 | 1.470 |
Why?
|
| Echo-Planar Imaging | 26 | 2022 | 659 | 1.360 |
Why?
|
| Image Processing, Computer-Assisted | 62 | 2023 | 8949 | 1.320 |
Why?
|
| Contrast Media | 61 | 2020 | 5300 | 1.320 |
Why?
|
| Oxygen | 36 | 2022 | 4189 | 1.300 |
Why?
|
| Cerebral Cortex | 33 | 2020 | 5709 | 1.160 |
Why?
|
| Brain Neoplasms | 37 | 2024 | 8861 | 1.110 |
Why?
|
| Image Enhancement | 33 | 2016 | 2921 | 1.010 |
Why?
|
| Pentetic Acid | 16 | 1998 | 213 | 0.920 |
Why?
|
| Glioma | 19 | 2020 | 3401 | 0.910 |
Why?
|
| Somatosensory Cortex | 15 | 2020 | 528 | 0.910 |
Why?
|
| Gadolinium DTPA | 16 | 2013 | 836 | 0.890 |
Why?
|
| Brain Ischemia | 26 | 2023 | 3265 | 0.890 |
Why?
|
| Nerve Net | 18 | 2020 | 2175 | 0.890 |
Why?
|
| Visual Cortex | 20 | 2021 | 1149 | 0.870 |
Why?
|
| Low Back Pain | 9 | 2020 | 956 | 0.850 |
Why?
|
| Motor Cortex | 19 | 2017 | 986 | 0.850 |
Why?
|
| Acupuncture Therapy | 8 | 2020 | 464 | 0.850 |
Why?
|
| Radiopharmaceuticals | 16 | 2022 | 2645 | 0.800 |
Why?
|
| Glutarates | 4 | 2018 | 236 | 0.780 |
Why?
|
| Visual Pathways | 4 | 2019 | 565 | 0.780 |
Why?
|
| Glioblastoma | 12 | 2024 | 3481 | 0.730 |
Why?
|
| Hemodynamics | 25 | 2021 | 4196 | 0.730 |
Why?
|
| Models, Neurological | 15 | 2017 | 1775 | 0.710 |
Why?
|
| Isocitrate Dehydrogenase | 5 | 2018 | 871 | 0.700 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2017 | 1100 | 0.690 |
Why?
|
| Body Water | 9 | 2008 | 343 | 0.680 |
Why?
|
| Brain Chemistry | 5 | 2014 | 982 | 0.650 |
Why?
|
| Organometallic Compounds | 13 | 1998 | 665 | 0.650 |
Why?
|
| Hypercapnia | 10 | 2020 | 260 | 0.650 |
Why?
|
| Humans | 424 | 2024 | 744366 | 0.640 |
Why?
|
| Adult | 240 | 2023 | 214052 | 0.640 |
Why?
|
| Image Interpretation, Computer-Assisted | 15 | 2017 | 3326 | 0.630 |
Why?
|
| Brain Stem | 10 | 2021 | 846 | 0.630 |
Why?
|
| Ovarian Neoplasms | 20 | 2015 | 4839 | 0.610 |
Why?
|
| Prefrontal Cortex | 15 | 2019 | 2147 | 0.600 |
Why?
|
| Cognition | 16 | 2020 | 6770 | 0.570 |
Why?
|
| Papio | 2 | 2017 | 656 | 0.570 |
Why?
|
| Reward | 6 | 2020 | 940 | 0.560 |
Why?
|
| Male | 266 | 2022 | 350115 | 0.560 |
Why?
|
| Cerebral Infarction | 8 | 2002 | 1011 | 0.540 |
Why?
|
| Acupuncture Points | 9 | 2016 | 101 | 0.530 |
Why?
|
| Spin Labels | 9 | 2022 | 332 | 0.530 |
Why?
|
| Basal Ganglia | 8 | 2019 | 546 | 0.530 |
Why?
|
| Fluorodeoxyglucose F18 | 14 | 2022 | 2016 | 0.530 |
Why?
|
| Female | 251 | 2022 | 380193 | 0.530 |
Why?
|
| Neural Pathways | 14 | 2020 | 2974 | 0.520 |
Why?
|
| Brain Diseases | 12 | 2022 | 1563 | 0.520 |
Why?
|
| Carbon Dioxide | 9 | 2021 | 1150 | 0.520 |
Why?
|
| Vaccines | 1 | 2024 | 823 | 0.510 |
Why?
|
| Uterine Cervical Neoplasms | 11 | 2022 | 2020 | 0.510 |
Why?
|
| Neoplasm Staging | 19 | 2020 | 11031 | 0.500 |
Why?
|
| Cocaine | 11 | 2012 | 1007 | 0.500 |
Why?
|
| Tomography, Emission-Computed | 16 | 2004 | 1144 | 0.490 |
Why?
|
| Blood-Brain Barrier | 7 | 2017 | 1019 | 0.490 |
Why?
|
| Microscopy | 3 | 2009 | 902 | 0.480 |
Why?
|
| Water | 9 | 2022 | 1395 | 0.470 |
Why?
|
| Middle Aged | 162 | 2022 | 213390 | 0.460 |
Why?
|
| Sensory Receptor Cells | 2 | 2017 | 493 | 0.450 |
Why?
|
| Receptors, Dopamine D3 | 4 | 2017 | 110 | 0.440 |
Why?
|
| Visual Perception | 10 | 2019 | 1420 | 0.440 |
Why?
|
| Rats, Sprague-Dawley | 45 | 2018 | 8300 | 0.430 |
Why?
|
| Neuronal Plasticity | 10 | 2020 | 1423 | 0.430 |
Why?
|
| Cocaine-Related Disorders | 5 | 2011 | 460 | 0.430 |
Why?
|
| Amyotrophic Lateral Sclerosis | 6 | 2021 | 1414 | 0.420 |
Why?
|
| Abdomen | 5 | 2018 | 1118 | 0.420 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 814 | 0.420 |
Why?
|
| Stroke | 16 | 2023 | 9981 | 0.410 |
Why?
|
| Information Dissemination | 3 | 2015 | 1099 | 0.410 |
Why?
|
| Oxygen Consumption | 9 | 2021 | 1868 | 0.410 |
Why?
|
| Imaging, Three-Dimensional | 9 | 2022 | 4042 | 0.400 |
Why?
|
| Functional Laterality | 15 | 2008 | 2290 | 0.400 |
Why?
|
| Receptors, Dopamine D2 | 5 | 2017 | 475 | 0.400 |
Why?
|
| Corpus Striatum | 15 | 2016 | 1221 | 0.390 |
Why?
|
| Rectal Neoplasms | 1 | 2020 | 1205 | 0.390 |
Why?
|
| Central Nervous System Diseases | 1 | 2015 | 518 | 0.380 |
Why?
|
| Genes, BRCA1 | 8 | 2015 | 781 | 0.380 |
Why?
|
| Rats | 63 | 2016 | 24252 | 0.380 |
Why?
|
| Sensitivity and Specificity | 36 | 2022 | 14723 | 0.380 |
Why?
|
| Neurosciences | 2 | 2013 | 348 | 0.380 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 506 | 0.380 |
Why?
|
| Neuroglia | 4 | 2017 | 928 | 0.370 |
Why?
|
| Young Adult | 48 | 2022 | 56429 | 0.370 |
Why?
|
| Israel | 3 | 2024 | 796 | 0.360 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 1170 | 0.360 |
Why?
|
| Blast Injuries | 2 | 2023 | 302 | 0.340 |
Why?
|
| Magnetic Resonance Angiography | 11 | 2019 | 1443 | 0.340 |
Why?
|
| Manganese Compounds | 1 | 2009 | 27 | 0.340 |
Why?
|
| Microcirculation | 10 | 2017 | 1287 | 0.340 |
Why?
|
| Attention | 6 | 2003 | 2397 | 0.340 |
Why?
|
| Verbal Learning | 4 | 2000 | 468 | 0.330 |
Why?
|
| Animals | 127 | 2021 | 168768 | 0.330 |
Why?
|
| Genes, BRCA2 | 6 | 2015 | 618 | 0.330 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 4 | 2000 | 250 | 0.320 |
Why?
|
| Vaccination | 1 | 2021 | 3279 | 0.320 |
Why?
|
| Oxides | 9 | 2007 | 405 | 0.320 |
Why?
|
| Pandemics | 5 | 2024 | 8385 | 0.320 |
Why?
|
| Electromagnetic Phenomena | 2 | 2021 | 161 | 0.320 |
Why?
|
| Neurons | 16 | 2020 | 9340 | 0.320 |
Why?
|
| Blood Flow Velocity | 18 | 2020 | 1423 | 0.320 |
Why?
|
| Habituation, Psychophysiologic | 3 | 2016 | 154 | 0.310 |
Why?
|
| Nerve Fibers, Myelinated | 3 | 2009 | 957 | 0.310 |
Why?
|
| Gadolinium | 9 | 2017 | 952 | 0.310 |
Why?
|
| Memory | 9 | 2001 | 2174 | 0.310 |
Why?
|
| Abdominal Neoplasms | 2 | 2021 | 292 | 0.310 |
Why?
|
| Computer Simulation | 17 | 2018 | 6194 | 0.310 |
Why?
|
| Aged | 94 | 2022 | 163288 | 0.300 |
Why?
|
| Mental Recall | 3 | 1998 | 1206 | 0.300 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2022 | 387 | 0.300 |
Why?
|
| Databases, Factual | 4 | 2018 | 7730 | 0.300 |
Why?
|
| Dopamine | 9 | 2016 | 1591 | 0.300 |
Why?
|
| Blood Vessels | 6 | 2014 | 1125 | 0.300 |
Why?
|
| Evoked Potentials, Somatosensory | 7 | 2016 | 243 | 0.300 |
Why?
|
| Diagnostic Imaging | 7 | 2023 | 3508 | 0.290 |
Why?
|
| Coma | 2 | 2021 | 475 | 0.290 |
Why?
|
| Pruritus | 3 | 2015 | 361 | 0.290 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 2865 | 0.280 |
Why?
|
| Psychomotor Performance | 6 | 2020 | 1901 | 0.280 |
Why?
|
| Touch Perception | 2 | 2020 | 114 | 0.280 |
Why?
|
| Dopamine Uptake Inhibitors | 6 | 2011 | 312 | 0.280 |
Why?
|
| Chlorides | 1 | 2009 | 667 | 0.280 |
Why?
|
| Recovery of Function | 8 | 2021 | 2926 | 0.270 |
Why?
|
| Neovascularization, Pathologic | 7 | 2016 | 2638 | 0.270 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2015 | 271 | 0.270 |
Why?
|
| Neurotoxins | 9 | 1998 | 237 | 0.270 |
Why?
|
| Whole Body Imaging | 3 | 2017 | 280 | 0.270 |
Why?
|
| Fingers | 7 | 2003 | 513 | 0.270 |
Why?
|
| Infarction, Middle Cerebral Artery | 6 | 2008 | 475 | 0.260 |
Why?
|
| Reproducibility of Results | 28 | 2022 | 19905 | 0.260 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2015 | 484 | 0.260 |
Why?
|
| Algorithms | 23 | 2024 | 13882 | 0.260 |
Why?
|
| Physicians | 1 | 2023 | 4567 | 0.260 |
Why?
|
| Photic Stimulation | 22 | 2016 | 2026 | 0.260 |
Why?
|
| Rest | 4 | 2020 | 901 | 0.260 |
Why?
|
| Reference Values | 20 | 2008 | 4982 | 0.260 |
Why?
|
| Huntington Disease | 6 | 2000 | 1124 | 0.260 |
Why?
|
| Biomedical Research | 6 | 2015 | 3309 | 0.250 |
Why?
|
| Ischemic Attack, Transient | 4 | 2003 | 935 | 0.250 |
Why?
|
| Gyrus Cinguli | 6 | 2012 | 1091 | 0.250 |
Why?
|
| Regional Blood Flow | 13 | 2004 | 1525 | 0.250 |
Why?
|
| Adenocarcinoma | 6 | 2006 | 6364 | 0.250 |
Why?
|
| Auditory Perception | 4 | 1998 | 569 | 0.250 |
Why?
|
| Cerebral Veins | 3 | 2014 | 156 | 0.240 |
Why?
|
| Breast Neoplasms | 12 | 2017 | 20824 | 0.240 |
Why?
|
| Neurology | 1 | 2012 | 763 | 0.240 |
Why?
|
| Temporal Lobe | 6 | 2001 | 1670 | 0.240 |
Why?
|
| Iron | 11 | 2007 | 1774 | 0.240 |
Why?
|
| Diffusion | 11 | 2011 | 832 | 0.240 |
Why?
|
| Pain Threshold | 6 | 2020 | 584 | 0.240 |
Why?
|
| Military Personnel | 2 | 2023 | 1133 | 0.240 |
Why?
|
| Isoflurane | 1 | 2007 | 380 | 0.240 |
Why?
|
| Multiple Sclerosis | 7 | 2014 | 3079 | 0.240 |
Why?
|
| Electric Stimulation | 11 | 2011 | 1767 | 0.240 |
Why?
|
| Autonomic Nervous System | 3 | 2019 | 672 | 0.230 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2021 | 20130 | 0.230 |
Why?
|
| Raclopride | 3 | 2021 | 97 | 0.230 |
Why?
|
| Memory, Short-Term | 3 | 2016 | 977 | 0.230 |
Why?
|
| Albumins | 1 | 2006 | 568 | 0.230 |
Why?
|
| Cerebrovascular Disorders | 7 | 2003 | 1504 | 0.230 |
Why?
|
| Aflatoxins | 1 | 2022 | 10 | 0.220 |
Why?
|
| Nitric Oxide Synthase | 2 | 1997 | 915 | 0.220 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 1996 | 520 | 0.220 |
Why?
|
| Pattern Recognition, Visual | 5 | 2001 | 824 | 0.220 |
Why?
|
| Behavior, Animal | 7 | 2017 | 1881 | 0.220 |
Why?
|
| Frontal Lobe | 6 | 2012 | 1406 | 0.220 |
Why?
|
| Respiration | 3 | 2020 | 1653 | 0.220 |
Why?
|
| Phantoms, Imaging | 8 | 2021 | 2480 | 0.220 |
Why?
|
| Axons | 3 | 2020 | 1685 | 0.220 |
Why?
|
| Adolescent | 43 | 2021 | 85779 | 0.220 |
Why?
|
| Brain Edema | 4 | 2007 | 617 | 0.220 |
Why?
|
| Migraine Disorders | 5 | 2017 | 1620 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2021 | 9240 | 0.210 |
Why?
|
| Language | 6 | 1999 | 1471 | 0.210 |
Why?
|
| Energy Metabolism | 12 | 2016 | 2897 | 0.210 |
Why?
|
| Auditory Cortex | 5 | 2003 | 346 | 0.210 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2016 | 664 | 0.210 |
Why?
|
| Glucose | 8 | 2016 | 4398 | 0.210 |
Why?
|
| Learning | 4 | 2018 | 1711 | 0.210 |
Why?
|
| Anesthetics, Inhalation | 1 | 2007 | 570 | 0.210 |
Why?
|
| Indoles | 2 | 2015 | 1839 | 0.210 |
Why?
|
| Alzheimer Disease | 7 | 2021 | 8038 | 0.210 |
Why?
|
| Amphetamine | 6 | 2009 | 225 | 0.210 |
Why?
|
| Signal Processing, Computer-Assisted | 6 | 2016 | 1534 | 0.210 |
Why?
|
| Supratentorial Neoplasms | 2 | 2004 | 160 | 0.210 |
Why?
|
| Systems Integration | 4 | 2015 | 440 | 0.200 |
Why?
|
| Deoxyglucose | 2 | 2008 | 337 | 0.200 |
Why?
|
| Transcranial Magnetic Stimulation | 4 | 2021 | 1433 | 0.200 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 2 | 2020 | 292 | 0.200 |
Why?
|
| Vaginal Smears | 2 | 2007 | 511 | 0.200 |
Why?
|
| Pain | 8 | 2017 | 4988 | 0.200 |
Why?
|
| Reaction Time | 11 | 2013 | 2098 | 0.200 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2022 | 94 | 0.200 |
Why?
|
| Myelitis | 1 | 2001 | 53 | 0.200 |
Why?
|
| Artifacts | 10 | 2018 | 1904 | 0.200 |
Why?
|
| Movement | 6 | 2017 | 1471 | 0.200 |
Why?
|
| Parietal Lobe | 7 | 2012 | 838 | 0.200 |
Why?
|
| Motion Perception | 6 | 2012 | 408 | 0.190 |
Why?
|
| Arousal | 5 | 2021 | 1164 | 0.190 |
Why?
|
| Lateral Thalamic Nuclei | 1 | 2020 | 8 | 0.190 |
Why?
|
| Capillary Permeability | 4 | 2019 | 798 | 0.190 |
Why?
|
| Inositol | 1 | 2021 | 218 | 0.190 |
Why?
|
| Patient Participation | 3 | 2001 | 1457 | 0.190 |
Why?
|
| Receptors, Dopamine | 3 | 2000 | 295 | 0.190 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2021 | 105 | 0.190 |
Why?
|
| Aging | 11 | 2023 | 8664 | 0.190 |
Why?
|
| Brain Concussion | 2 | 2022 | 1320 | 0.190 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2020 | 41 | 0.190 |
Why?
|
| Mutation | 14 | 2018 | 29786 | 0.190 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2021 | 2038 | 0.190 |
Why?
|
| Speech | 3 | 2000 | 541 | 0.180 |
Why?
|
| Meglumine | 2 | 1998 | 149 | 0.180 |
Why?
|
| Psychomotor Disorders | 1 | 2001 | 152 | 0.180 |
Why?
|
| Hysterectomy | 4 | 2008 | 927 | 0.180 |
Why?
|
| Agnosia | 1 | 2020 | 66 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 221 | 0.180 |
Why?
|
| CA-125 Antigen | 1 | 2002 | 286 | 0.170 |
Why?
|
| Hand Strength | 1 | 2002 | 448 | 0.170 |
Why?
|
| Respiratory Rate | 1 | 2020 | 162 | 0.170 |
Why?
|
| Diffusion Tensor Imaging | 7 | 2022 | 2305 | 0.170 |
Why?
|
| Macaca mulatta | 10 | 2017 | 2377 | 0.170 |
Why?
|
| Health Planning | 1 | 2021 | 238 | 0.170 |
Why?
|
| Lactates | 10 | 1998 | 432 | 0.170 |
Why?
|
| Adipose Tissue | 7 | 1995 | 3280 | 0.170 |
Why?
|
| Motor Neurons | 4 | 2017 | 844 | 0.170 |
Why?
|
| Genetic Counseling | 3 | 2015 | 600 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2019 | 11525 | 0.170 |
Why?
|
| Catastrophization | 2 | 2019 | 316 | 0.170 |
Why?
|
| Long QT Syndrome | 1 | 2023 | 453 | 0.170 |
Why?
|
| Magnetics | 9 | 2008 | 606 | 0.170 |
Why?
|
| Touch | 4 | 2009 | 306 | 0.170 |
Why?
|
| Information Services | 1 | 2000 | 244 | 0.170 |
Why?
|
| Brain Injuries | 3 | 2022 | 2029 | 0.160 |
Why?
|
| Neuroprotective Agents | 3 | 2008 | 941 | 0.160 |
Why?
|
| Mentors | 1 | 2023 | 631 | 0.160 |
Why?
|
| Cerebrospinal Fluid | 2 | 2019 | 535 | 0.160 |
Why?
|
| Cerebral Angiography | 3 | 2019 | 1285 | 0.160 |
Why?
|
| Expert Testimony | 1 | 2021 | 356 | 0.160 |
Why?
|
| Hypertension, Malignant | 1 | 1998 | 19 | 0.160 |
Why?
|
| Qi | 2 | 2007 | 15 | 0.160 |
Why?
|
| Cognition Disorders | 4 | 2013 | 4043 | 0.160 |
Why?
|
| Intracranial Hemorrhages | 2 | 2021 | 855 | 0.160 |
Why?
|
| Serotonin 5-HT1 Receptor Antagonists | 1 | 2017 | 9 | 0.160 |
Why?
|
| Receptors, GABA | 4 | 2023 | 287 | 0.160 |
Why?
|
| Molecular Imaging | 2 | 2016 | 828 | 0.160 |
Why?
|
| Perfusion Imaging | 1 | 2019 | 195 | 0.160 |
Why?
|
| Pain Measurement | 9 | 2020 | 3420 | 0.160 |
Why?
|
| RNA Probes | 3 | 2007 | 113 | 0.160 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2000 | 172 | 0.160 |
Why?
|
| Hemiplegia | 2 | 1997 | 135 | 0.160 |
Why?
|
| Infertility, Female | 3 | 2001 | 788 | 0.160 |
Why?
|
| Drug Partial Agonism | 1 | 2017 | 24 | 0.160 |
Why?
|
| Superior Colliculi | 1 | 2018 | 99 | 0.160 |
Why?
|
| Paired-Associate Learning | 1 | 1997 | 52 | 0.160 |
Why?
|
| Brain Infarction | 3 | 2023 | 299 | 0.150 |
Why?
|
| Dopamine Agonists | 4 | 2015 | 355 | 0.150 |
Why?
|
| Cerebral Arteries | 3 | 2014 | 494 | 0.150 |
Why?
|
| Persistent Vegetative State | 1 | 2020 | 260 | 0.150 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2017 | 43 | 0.150 |
Why?
|
| Respiratory-Gated Imaging Techniques | 1 | 2018 | 71 | 0.150 |
Why?
|
| Quinpirole | 2 | 2015 | 33 | 0.150 |
Why?
|
| Models, Theoretical | 7 | 2021 | 3589 | 0.150 |
Why?
|
| Retrospective Studies | 22 | 2023 | 77460 | 0.150 |
Why?
|
| Reperfusion | 1 | 1998 | 284 | 0.150 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1999 | 648 | 0.150 |
Why?
|
| Tegmentum Mesencephali | 1 | 2017 | 59 | 0.150 |
Why?
|
| Psychopathology | 1 | 2020 | 409 | 0.150 |
Why?
|
| Proton Pumps | 1 | 1996 | 30 | 0.150 |
Why?
|
| Cognitive Science | 1 | 1996 | 14 | 0.150 |
Why?
|
| Motor Neuron Disease | 1 | 2017 | 99 | 0.150 |
Why?
|
| Debridement | 1 | 2000 | 492 | 0.150 |
Why?
|
| Fertility Agents, Female | 1 | 1997 | 99 | 0.150 |
Why?
|
| Decision Making | 3 | 2001 | 3888 | 0.150 |
Why?
|
| Cats | 6 | 1998 | 1000 | 0.150 |
Why?
|
| Geniculate Bodies | 1 | 2018 | 163 | 0.150 |
Why?
|
| Magnetite Nanoparticles | 3 | 2014 | 321 | 0.150 |
Why?
|
| Lumbar Vertebrae | 4 | 2017 | 1848 | 0.140 |
Why?
|
| Neural Inhibition | 3 | 2011 | 602 | 0.140 |
Why?
|
| Brain Damage, Chronic | 2 | 1997 | 265 | 0.140 |
Why?
|
| Obsessive-Compulsive Disorder | 3 | 2011 | 1444 | 0.140 |
Why?
|
| Anisotropy | 8 | 2020 | 1265 | 0.140 |
Why?
|
| Lymph Node Excision | 4 | 2009 | 1262 | 0.140 |
Why?
|
| Moyamoya Disease | 1 | 2019 | 238 | 0.140 |
Why?
|
| Limbic System | 3 | 2010 | 426 | 0.140 |
Why?
|
| Polylysine | 1 | 1996 | 133 | 0.140 |
Why?
|
| Receptors, Progesterone | 2 | 2017 | 1098 | 0.140 |
Why?
|
| Pelvis | 2 | 2020 | 730 | 0.140 |
Why?
|
| Gentisates | 1 | 1995 | 5 | 0.140 |
Why?
|
| Heart | 10 | 2020 | 4464 | 0.140 |
Why?
|
| Aged, 80 and over | 28 | 2018 | 57776 | 0.140 |
Why?
|
| Sulfhydryl Compounds | 1 | 2017 | 298 | 0.140 |
Why?
|
| Affective Disorders, Psychotic | 1 | 1997 | 191 | 0.140 |
Why?
|
| Corpus Callosum | 3 | 2019 | 737 | 0.140 |
Why?
|
| Fluorine Radioisotopes | 2 | 2017 | 442 | 0.140 |
Why?
|
| Adrenoleukodystrophy | 1 | 2017 | 123 | 0.140 |
Why?
|
| Pituitary-Adrenal System | 1 | 1999 | 553 | 0.140 |
Why?
|
| Laser-Doppler Flowmetry | 4 | 2007 | 242 | 0.140 |
Why?
|
| Lactic Acid | 9 | 1998 | 1132 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2022 | 665 | 0.130 |
Why?
|
| Anesthesia | 1 | 2007 | 1561 | 0.130 |
Why?
|
| Prognosis | 15 | 2020 | 29060 | 0.130 |
Why?
|
| Afterimage | 1 | 1995 | 8 | 0.130 |
Why?
|
| Parkinson Disease, Secondary | 1 | 1996 | 126 | 0.130 |
Why?
|
| Receptors, Dopamine D1 | 2 | 2016 | 291 | 0.130 |
Why?
|
| Cervix Uteri | 1 | 1999 | 590 | 0.130 |
Why?
|
| Hippocampus | 7 | 2008 | 3675 | 0.130 |
Why?
|
| Survival Analysis | 11 | 2016 | 10252 | 0.130 |
Why?
|
| Neurodegenerative Diseases | 3 | 2021 | 1061 | 0.130 |
Why?
|
| Lumbosacral Region | 1 | 2017 | 310 | 0.130 |
Why?
|
| Blood Volume Determination | 1 | 2015 | 43 | 0.130 |
Why?
|
| Aspartic Acid | 5 | 2017 | 576 | 0.130 |
Why?
|
| Motor Activity | 6 | 2015 | 2715 | 0.130 |
Why?
|
| Heterocyclic Compounds | 1 | 1996 | 249 | 0.130 |
Why?
|
| Brain Waves | 1 | 2019 | 401 | 0.130 |
Why?
|
| Conditioning, Operant | 2 | 2018 | 313 | 0.130 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 1587 | 0.130 |
Why?
|
| Models, Structural | 8 | 1998 | 361 | 0.130 |
Why?
|
| Folate Receptor 1 | 1 | 2014 | 36 | 0.130 |
Why?
|
| Pilot Projects | 8 | 2022 | 8319 | 0.130 |
Why?
|
| Time Factors | 34 | 2014 | 40075 | 0.130 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2008 | 337 | 0.130 |
Why?
|
| Quinoxalines | 1 | 1997 | 290 | 0.130 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2017 | 896 | 0.130 |
Why?
|
| Back Pain | 1 | 2019 | 545 | 0.130 |
Why?
|
| Physical Phenomena | 1 | 2014 | 46 | 0.120 |
Why?
|
| Cohort Studies | 14 | 2021 | 40559 | 0.120 |
Why?
|
| Vagus Nerve | 1 | 2017 | 439 | 0.120 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 644 | 0.120 |
Why?
|
| Anticipation, Psychological | 2 | 2012 | 87 | 0.120 |
Why?
|
| Bone Marrow | 7 | 1995 | 2948 | 0.120 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 3 | 2011 | 271 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2009 | 638 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 1 | 2019 | 567 | 0.120 |
Why?
|
| Receptors, Serotonin, 5-HT4 | 1 | 2013 | 16 | 0.120 |
Why?
|
| Cholangiocarcinoma | 1 | 2019 | 516 | 0.120 |
Why?
|
| Ferrosoferric Oxide | 9 | 2008 | 360 | 0.120 |
Why?
|
| Computer Communication Networks | 2 | 2018 | 295 | 0.120 |
Why?
|
| Forelimb | 5 | 2015 | 122 | 0.120 |
Why?
|
| Evoked Potentials | 7 | 2008 | 1056 | 0.120 |
Why?
|
| Cues | 3 | 2018 | 875 | 0.120 |
Why?
|
| Physical Stimulation | 6 | 2019 | 525 | 0.120 |
Why?
|
| Amygdala | 2 | 2004 | 1315 | 0.120 |
Why?
|
| Arginine | 1 | 1998 | 944 | 0.120 |
Why?
|
| Ovariectomy | 3 | 2011 | 661 | 0.120 |
Why?
|
| Dermatitis, Atopic | 3 | 2015 | 654 | 0.120 |
Why?
|
| Spinal Cord | 3 | 2013 | 1810 | 0.120 |
Why?
|
| Acupuncture Analgesia | 3 | 2009 | 62 | 0.120 |
Why?
|
| Hyperthermia, Induced | 1 | 2017 | 403 | 0.120 |
Why?
|
| Vision Disorders | 3 | 2012 | 1058 | 0.120 |
Why?
|
| Sensation | 3 | 2007 | 336 | 0.120 |
Why?
|
| Electrophysiology | 6 | 2001 | 1308 | 0.110 |
Why?
|
| Coronary Circulation | 6 | 1996 | 1572 | 0.110 |
Why?
|
| Vomiting | 1 | 2016 | 637 | 0.110 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 528 | 0.110 |
Why?
|
| Cell Size | 1 | 1995 | 643 | 0.110 |
Why?
|
| Internet | 1 | 2006 | 3056 | 0.110 |
Why?
|
| Caudate Nucleus | 2 | 1996 | 393 | 0.110 |
Why?
|
| Calcium Signaling | 1 | 2018 | 721 | 0.110 |
Why?
|
| Molecular Probe Techniques | 1 | 1994 | 119 | 0.110 |
Why?
|
| Germ-Line Mutation | 5 | 2015 | 1788 | 0.110 |
Why?
|
| Occipital Lobe | 2 | 1999 | 379 | 0.110 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2015 | 221 | 0.110 |
Why?
|
| Acetamides | 1 | 2015 | 249 | 0.110 |
Why?
|
| Thalamus | 2 | 2014 | 1023 | 0.110 |
Why?
|
| Pancreas | 1 | 2000 | 1687 | 0.110 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2015 | 431 | 0.110 |
Why?
|
| Arterioles | 4 | 2018 | 254 | 0.110 |
Why?
|
| Putamen | 1 | 1994 | 291 | 0.110 |
Why?
|
| Dopamine Antagonists | 5 | 2015 | 296 | 0.110 |
Why?
|
| Sound | 1 | 2014 | 260 | 0.110 |
Why?
|
| Face | 1 | 1999 | 994 | 0.110 |
Why?
|
| Facial Expression | 1 | 1996 | 508 | 0.110 |
Why?
|
| Ovulation | 1 | 1993 | 189 | 0.110 |
Why?
|
| Leukoaraiosis | 1 | 2013 | 120 | 0.110 |
Why?
|
| gamma-Aminobutyric Acid | 5 | 2014 | 1121 | 0.110 |
Why?
|
| Paraparesis, Tropical Spastic | 1 | 2012 | 32 | 0.110 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 198 | 0.110 |
Why?
|
| Magnetoencephalography | 4 | 2013 | 624 | 0.100 |
Why?
|
| Feasibility Studies | 7 | 2022 | 5077 | 0.100 |
Why?
|
| Sports | 3 | 1995 | 688 | 0.100 |
Why?
|
| Fourier Analysis | 9 | 1999 | 447 | 0.100 |
Why?
|
| Anti-Retroviral Agents | 1 | 2022 | 1714 | 0.100 |
Why?
|
| Saccades | 2 | 2012 | 246 | 0.100 |
Why?
|
| Mannitol | 1 | 2012 | 181 | 0.100 |
Why?
|
| Reading | 4 | 2000 | 558 | 0.100 |
Why?
|
| Drug-Seeking Behavior | 1 | 2012 | 48 | 0.100 |
Why?
|
| Malonates | 4 | 1998 | 42 | 0.100 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2016 | 388 | 0.100 |
Why?
|
| Heart Rate | 6 | 2020 | 4092 | 0.100 |
Why?
|
| Oximetry | 2 | 2011 | 471 | 0.100 |
Why?
|
| Acute Disease | 7 | 2008 | 7147 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 3 | 2009 | 1148 | 0.100 |
Why?
|
| Information Storage and Retrieval | 2 | 2015 | 824 | 0.100 |
Why?
|
| Laparoscopy | 2 | 2004 | 2150 | 0.100 |
Why?
|
| Benzamides | 1 | 2017 | 1379 | 0.100 |
Why?
|
| Electroacupuncture | 2 | 2009 | 60 | 0.100 |
Why?
|
| Partial Pressure | 3 | 2020 | 254 | 0.100 |
Why?
|
| Dexamethasone | 1 | 1999 | 1951 | 0.100 |
Why?
|
| Quinolines | 1 | 2016 | 732 | 0.100 |
Why?
|
| Salpingostomy | 1 | 2011 | 11 | 0.100 |
Why?
|
| Software | 1 | 2006 | 4441 | 0.100 |
Why?
|
| Hydrocortisone | 1 | 1999 | 1826 | 0.100 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 1991 | 44 | 0.100 |
Why?
|
| Foramen Magnum | 1 | 1991 | 36 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 10 | 2012 | 21833 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2018 | 3480 | 0.100 |
Why?
|
| Carcinoma | 3 | 1999 | 2375 | 0.100 |
Why?
|
| Sacrococcygeal Region | 1 | 1991 | 52 | 0.100 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2015 | 450 | 0.100 |
Why?
|
| Pyramidal Tracts | 1 | 2013 | 256 | 0.100 |
Why?
|
| Hand | 5 | 2009 | 884 | 0.100 |
Why?
|
| Synapses | 1 | 2020 | 1728 | 0.100 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2013 | 409 | 0.100 |
Why?
|
| Polyethylene Glycols | 1 | 1996 | 1182 | 0.100 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2012 | 197 | 0.100 |
Why?
|
| Trigeminal Nerve | 2 | 2016 | 249 | 0.100 |
Why?
|
| Propionates | 4 | 1998 | 169 | 0.100 |
Why?
|
| Analysis of Variance | 8 | 2016 | 6366 | 0.100 |
Why?
|
| Monte Carlo Method | 7 | 1998 | 1254 | 0.100 |
Why?
|
| Placebo Effect | 3 | 2009 | 502 | 0.090 |
Why?
|
| Disease | 1 | 2016 | 680 | 0.090 |
Why?
|
| Schizophrenia | 5 | 2013 | 6882 | 0.090 |
Why?
|
| Disease Models, Animal | 12 | 2016 | 18034 | 0.090 |
Why?
|
| Hyperalgesia | 2 | 2019 | 502 | 0.090 |
Why?
|
| Radiology Information Systems | 1 | 2015 | 523 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1999 | 1524 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 4 | 2011 | 2716 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2017 | 10943 | 0.090 |
Why?
|
| Papilloma | 1 | 1991 | 148 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2001 | 4034 | 0.090 |
Why?
|
| Angiography | 2 | 1986 | 1639 | 0.090 |
Why?
|
| Skull Neoplasms | 1 | 1991 | 173 | 0.090 |
Why?
|
| Injections, Intraventricular | 2 | 2009 | 231 | 0.090 |
Why?
|
| Bone Marrow Diseases | 2 | 1989 | 231 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2000 | 2278 | 0.090 |
Why?
|
| Retina | 2 | 2012 | 2616 | 0.090 |
Why?
|
| BRCA1 Protein | 4 | 2002 | 1149 | 0.090 |
Why?
|
| Acupuncture | 1 | 2010 | 90 | 0.090 |
Why?
|
| Dominance, Cerebral | 4 | 2004 | 635 | 0.090 |
Why?
|
| Patient Satisfaction | 3 | 2011 | 3395 | 0.090 |
Why?
|
| Disease-Free Survival | 8 | 2014 | 6896 | 0.090 |
Why?
|
| Nerve Degeneration | 2 | 2009 | 748 | 0.090 |
Why?
|
| Executive Function | 1 | 2018 | 1364 | 0.090 |
Why?
|
| Ventral Tegmental Area | 1 | 2010 | 142 | 0.090 |
Why?
|
| Colorectal Neoplasms | 3 | 2019 | 6773 | 0.090 |
Why?
|
| Child | 16 | 2020 | 77709 | 0.090 |
Why?
|
| Mathematics | 4 | 1998 | 728 | 0.090 |
Why?
|
| Piperidines | 2 | 2017 | 1602 | 0.090 |
Why?
|
| Diagnostic Errors | 2 | 2015 | 1257 | 0.090 |
Why?
|
| Ontario | 3 | 2007 | 383 | 0.090 |
Why?
|
| DNA Mismatch Repair | 1 | 2012 | 426 | 0.090 |
Why?
|
| Models, Anatomic | 1 | 2013 | 691 | 0.080 |
Why?
|
| Models, Biological | 8 | 2013 | 9584 | 0.080 |
Why?
|
| Metabolome | 1 | 2016 | 895 | 0.080 |
Why?
|
| Conditioning, Classical | 1 | 2012 | 366 | 0.080 |
Why?
|
| Biotechnology | 1 | 2011 | 281 | 0.080 |
Why?
|
| Nausea | 1 | 2012 | 674 | 0.080 |
Why?
|
| Goals | 1 | 2014 | 707 | 0.080 |
Why?
|
| Comprehension | 1 | 2014 | 610 | 0.080 |
Why?
|
| Radionuclide Imaging | 5 | 2021 | 2031 | 0.080 |
Why?
|
| Substantia Nigra | 1 | 2010 | 353 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 1142 | 0.080 |
Why?
|
| Head | 2 | 2014 | 880 | 0.080 |
Why?
|
| Statistics as Topic | 5 | 2015 | 2373 | 0.080 |
Why?
|
| Prospective Studies | 15 | 2021 | 53290 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 1381 | 0.080 |
Why?
|
| Carbon Radioisotopes | 3 | 2017 | 577 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 2190 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2282 | 0.080 |
Why?
|
| Infusions, Intravenous | 3 | 2018 | 2274 | 0.080 |
Why?
|
| Middle Cerebral Artery | 2 | 2020 | 264 | 0.080 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2015 | 1205 | 0.080 |
Why?
|
| Choroid Plexus | 1 | 1991 | 231 | 0.080 |
Why?
|
| Immunohistochemistry | 8 | 2016 | 11366 | 0.080 |
Why?
|
| Energy Transfer | 1 | 2008 | 109 | 0.080 |
Why?
|
| Electroencephalography | 6 | 2020 | 6151 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 1415 | 0.080 |
Why?
|
| Metacarpus | 1 | 2007 | 35 | 0.080 |
Why?
|
| Robotics | 2 | 2013 | 899 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2009 | 575 | 0.080 |
Why?
|
| Rats, Inbred SHR | 5 | 2002 | 195 | 0.080 |
Why?
|
| Parotid Gland | 1 | 1989 | 168 | 0.080 |
Why?
|
| Migraine with Aura | 2 | 2001 | 203 | 0.080 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2011 | 324 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 2949 | 0.080 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 39052 | 0.080 |
Why?
|
| Lithium Chloride | 1 | 2008 | 87 | 0.080 |
Why?
|
| Memory Disorders | 3 | 2004 | 1186 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 1994 | 1701 | 0.080 |
Why?
|
| Ependymoma | 1 | 1991 | 334 | 0.080 |
Why?
|
| Entorhinal Cortex | 1 | 2009 | 272 | 0.080 |
Why?
|
| Case-Control Studies | 10 | 2020 | 21748 | 0.080 |
Why?
|
| Statistics, Nonparametric | 4 | 2014 | 2887 | 0.080 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 1624 | 0.080 |
Why?
|
| Body Composition | 2 | 1995 | 2402 | 0.070 |
Why?
|
| Behavior | 4 | 2011 | 561 | 0.070 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2007 | 98 | 0.070 |
Why?
|
| Hyperesthesia | 1 | 2007 | 17 | 0.070 |
Why?
|
| Predictive Value of Tests | 11 | 2021 | 15078 | 0.070 |
Why?
|
| Astrocytoma | 2 | 2004 | 790 | 0.070 |
Why?
|
| Mice | 16 | 2020 | 81201 | 0.070 |
Why?
|
| Acoustic Stimulation | 7 | 2003 | 1216 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 3799 | 0.070 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 13693 | 0.070 |
Why?
|
| Receptor, erbB-2 | 1 | 2017 | 2417 | 0.070 |
Why?
|
| Vision, Ocular | 2 | 2009 | 464 | 0.070 |
Why?
|
| Cross-Sectional Studies | 9 | 2018 | 25039 | 0.070 |
Why?
|
| Neoplasm Proteins | 5 | 2001 | 3707 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 1862 | 0.070 |
Why?
|
| Paclitaxel | 3 | 2006 | 1708 | 0.070 |
Why?
|
| Protons | 5 | 1998 | 1127 | 0.070 |
Why?
|
| Jews | 2 | 2000 | 385 | 0.070 |
Why?
|
| Mental Processes | 1 | 2008 | 249 | 0.070 |
Why?
|
| Muscle, Skeletal | 3 | 1997 | 4925 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 3590 | 0.070 |
Why?
|
| Quinazolines | 4 | 2013 | 1356 | 0.070 |
Why?
|
| Bone and Bones | 4 | 2010 | 2576 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 13104 | 0.070 |
Why?
|
| Estrogens | 1 | 1993 | 1566 | 0.070 |
Why?
|
| Reperfusion Injury | 2 | 2007 | 1026 | 0.070 |
Why?
|
| Pyridines | 2 | 2015 | 2825 | 0.070 |
Why?
|
| Cell Transplantation | 2 | 1999 | 477 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 5534 | 0.070 |
Why?
|
| Form Perception | 2 | 1998 | 182 | 0.070 |
Why?
|
| Space Perception | 2 | 2000 | 475 | 0.070 |
Why?
|
| Creatine | 3 | 1999 | 421 | 0.070 |
Why?
|
| Spheroids, Cellular | 1 | 2008 | 351 | 0.070 |
Why?
|
| HIV Infections | 2 | 2022 | 16715 | 0.070 |
Why?
|
| Carboplatin | 2 | 2006 | 801 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2023 | 1915 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2020 | 1590 | 0.070 |
Why?
|
| Rotation | 3 | 2014 | 523 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2012 | 1534 | 0.070 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2006 | 84 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2001 | 3922 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 7 | 2002 | 2647 | 0.070 |
Why?
|
| Glutamine | 2 | 2017 | 579 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 1992 | 1520 | 0.070 |
Why?
|
| Social Adjustment | 3 | 1978 | 631 | 0.070 |
Why?
|
| Subtraction Technique | 3 | 2019 | 525 | 0.070 |
Why?
|
| Information Management | 1 | 2006 | 101 | 0.070 |
Why?
|
| Dementia | 2 | 1999 | 2518 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2002 | 1261 | 0.060 |
Why?
|
| Spine | 2 | 1992 | 1144 | 0.060 |
Why?
|
| Electromyography | 3 | 2002 | 1379 | 0.060 |
Why?
|
| Prosencephalon | 1 | 2007 | 303 | 0.060 |
Why?
|
| Liver | 4 | 1996 | 7475 | 0.060 |
Why?
|
| Blood Pressure | 8 | 2016 | 8551 | 0.060 |
Why?
|
| Rats, Inbred F344 | 2 | 1996 | 862 | 0.060 |
Why?
|
| Permeability | 2 | 2017 | 738 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2017 | 449 | 0.060 |
Why?
|
| Spinal Neoplasms | 2 | 1991 | 760 | 0.060 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 2 | 1996 | 30 | 0.060 |
Why?
|
| Collagen Type I | 1 | 2008 | 592 | 0.060 |
Why?
|
| Bone Neoplasms | 3 | 2015 | 2530 | 0.060 |
Why?
|
| Tomography | 2 | 1983 | 390 | 0.060 |
Why?
|
| Needles | 1 | 2007 | 449 | 0.060 |
Why?
|
| Gaucher Disease | 3 | 1995 | 112 | 0.060 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2004 | 37 | 0.060 |
Why?
|
| Ubiquinone | 2 | 1997 | 188 | 0.060 |
Why?
|
| Placebos | 4 | 2019 | 1676 | 0.060 |
Why?
|
| Speech Perception | 3 | 2000 | 490 | 0.060 |
Why?
|
| Leg | 3 | 1986 | 1116 | 0.060 |
Why?
|
| Estradiol | 1 | 1992 | 2020 | 0.060 |
Why?
|
| Dogs | 8 | 1994 | 3912 | 0.060 |
Why?
|
| Drug Delivery Systems | 3 | 2009 | 2219 | 0.060 |
Why?
|
| Dizocilpine Maleate | 4 | 2017 | 176 | 0.060 |
Why?
|
| Hemoglobins | 6 | 2008 | 1532 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 1656 | 0.060 |
Why?
|
| Peripheral Nerves | 1 | 2007 | 466 | 0.060 |
Why?
|
| Myocardium | 6 | 2007 | 4772 | 0.060 |
Why?
|
| Oligonucleotides | 1 | 2007 | 572 | 0.060 |
Why?
|
| Dye Dilution Technique | 1 | 2003 | 17 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2012 | 2740 | 0.060 |
Why?
|
| Pitch Discrimination | 1 | 2003 | 39 | 0.060 |
Why?
|
| Rabbits | 4 | 1995 | 4894 | 0.060 |
Why?
|
| Transcription, Genetic | 3 | 2007 | 7721 | 0.060 |
Why?
|
| Sleep | 1 | 2019 | 4622 | 0.060 |
Why?
|
| Nitro Compounds | 4 | 1998 | 74 | 0.060 |
Why?
|
| Leukemia | 1 | 1992 | 1510 | 0.060 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 13991 | 0.060 |
Why?
|
| Lymphatic Metastasis | 4 | 2009 | 2924 | 0.060 |
Why?
|
| Neuropsychological Tests | 6 | 2014 | 6994 | 0.060 |
Why?
|
| Motion | 2 | 2018 | 798 | 0.060 |
Why?
|
| Computer Systems | 2 | 2011 | 483 | 0.060 |
Why?
|
| Explosions | 1 | 2023 | 109 | 0.060 |
Why?
|
| Psychophysics | 2 | 2012 | 309 | 0.060 |
Why?
|
| Depth Perception | 1 | 2003 | 94 | 0.060 |
Why?
|
| Severity of Illness Index | 7 | 2016 | 15535 | 0.060 |
Why?
|
| Patient Readmission | 1 | 1997 | 3116 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 1062 | 0.060 |
Why?
|
| Demography | 2 | 2015 | 1655 | 0.060 |
Why?
|
| Radiography | 6 | 2013 | 7023 | 0.050 |
Why?
|
| Association | 1 | 2003 | 53 | 0.050 |
Why?
|
| Forearm | 2 | 2012 | 409 | 0.050 |
Why?
|
| Verbal Behavior | 2 | 2001 | 339 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2015 | 2304 | 0.050 |
Why?
|
| Cerebellar Cortex | 1 | 2003 | 107 | 0.050 |
Why?
|
| Heterozygote | 2 | 2011 | 2804 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
| Oligodendroglioma | 1 | 2004 | 279 | 0.050 |
Why?
|
| Sex Factors | 1 | 2016 | 10400 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
| Vasodilation | 2 | 2020 | 944 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2015 | 3444 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2009 | 13035 | 0.050 |
Why?
|
| Treatment Outcome | 11 | 2020 | 63107 | 0.050 |
Why?
|
| Epilepsies, Partial | 1 | 2006 | 436 | 0.050 |
Why?
|
| Genomics | 2 | 2015 | 5717 | 0.050 |
Why?
|
| Neurons, Afferent | 2 | 2019 | 506 | 0.050 |
Why?
|
| Blood Glucose | 3 | 2014 | 6254 | 0.050 |
Why?
|
| Uterine Neoplasms | 2 | 2006 | 1513 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 1997 | 1107 | 0.050 |
Why?
|
| Adenosine Triphosphate | 7 | 1998 | 2027 | 0.050 |
Why?
|
| Mitochondria | 5 | 1994 | 3514 | 0.050 |
Why?
|
| Microdialysis | 2 | 1999 | 158 | 0.050 |
Why?
|
| Brain Injury, Chronic | 1 | 2021 | 68 | 0.050 |
Why?
|
| Globus Pallidus | 1 | 2002 | 253 | 0.050 |
Why?
|
| Sterilization, Tubal | 1 | 2001 | 87 | 0.050 |
Why?
|
| Clinical Protocols | 2 | 2017 | 1461 | 0.050 |
Why?
|
| Dacarbazine | 2 | 2013 | 566 | 0.050 |
Why?
|
| Hemosiderin | 2 | 1990 | 43 | 0.050 |
Why?
|
| Parkinson Disease | 1 | 2014 | 2775 | 0.050 |
Why?
|
| Ferric Compounds | 3 | 2007 | 374 | 0.050 |
Why?
|
| Intelligence Tests | 2 | 1998 | 505 | 0.050 |
Why?
|
| Hot Temperature | 3 | 2016 | 1356 | 0.040 |
Why?
|
| N-Methylaspartate | 3 | 1995 | 231 | 0.040 |
Why?
|
| Bipolar Disorder | 1 | 1997 | 5027 | 0.040 |
Why?
|
| Dystonic Disorders | 1 | 2004 | 329 | 0.040 |
Why?
|
| Hyperoxia | 1 | 2002 | 262 | 0.040 |
Why?
|
| Exercise | 2 | 1993 | 5615 | 0.040 |
Why?
|
| Neuronavigation | 1 | 2021 | 167 | 0.040 |
Why?
|
| Emotions | 3 | 2012 | 2659 | 0.040 |
Why?
|
| Depression | 1 | 1999 | 7759 | 0.040 |
Why?
|
| Founder Effect | 1 | 2000 | 189 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2021 | 382 | 0.040 |
Why?
|
| Color Perception | 2 | 1998 | 213 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2021 | 570 | 0.040 |
Why?
|
| Thiothixene | 1 | 1978 | 3 | 0.040 |
Why?
|
| Sodium Chloride | 2 | 2018 | 625 | 0.040 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 85 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 6 | 2013 | 6036 | 0.040 |
Why?
|
| Phenotype | 1 | 2017 | 16367 | 0.040 |
Why?
|
| Ventilation | 1 | 1999 | 127 | 0.040 |
Why?
|
| Delta Rhythm | 1 | 2019 | 78 | 0.040 |
Why?
|
| Electromagnetic Fields | 1 | 2021 | 298 | 0.040 |
Why?
|
| Light | 2 | 2012 | 1374 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 2 | 2010 | 2727 | 0.040 |
Why?
|
| Smell | 1 | 2001 | 244 | 0.040 |
Why?
|
| Nanoparticles | 2 | 2008 | 1905 | 0.040 |
Why?
|
| Contraceptives, Oral | 1 | 2001 | 564 | 0.040 |
Why?
|
| Myocardial Contraction | 4 | 1995 | 1579 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 1992 | 3524 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 3 | 1991 | 1681 | 0.040 |
Why?
|
| Dysprosium | 2 | 1998 | 25 | 0.040 |
Why?
|
| Carotid Stenosis | 2 | 2007 | 854 | 0.040 |
Why?
|
| Fatty Liver | 1 | 1985 | 727 | 0.040 |
Why?
|
| Migraine without Aura | 1 | 1999 | 83 | 0.040 |
Why?
|
| Physical Therapy Modalities | 1 | 2002 | 550 | 0.040 |
Why?
|
| Apomorphine | 2 | 2000 | 150 | 0.040 |
Why?
|
| Sensory Thresholds | 1 | 2020 | 391 | 0.040 |
Why?
|
| Self Disclosure | 1 | 2000 | 251 | 0.040 |
Why?
|
| Sciatic Nerve | 1 | 2022 | 607 | 0.040 |
Why?
|
| Oxidation-Reduction | 4 | 1998 | 2184 | 0.040 |
Why?
|
| Post-Concussion Syndrome | 1 | 2021 | 219 | 0.040 |
Why?
|
| Medical Informatics | 1 | 2006 | 745 | 0.040 |
Why?
|
| Troponin T | 1 | 2023 | 754 | 0.040 |
Why?
|
| Transcription Factors | 4 | 2001 | 12207 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 1504 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2013 | 4232 | 0.040 |
Why?
|
| Nitric Oxide | 2 | 1998 | 2132 | 0.040 |
Why?
|
| Sleep, REM | 1 | 2021 | 595 | 0.040 |
Why?
|
| Tissue Distribution | 3 | 2013 | 2327 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2007 | 2052 | 0.040 |
Why?
|
| Auditory Pathways | 2 | 1998 | 233 | 0.040 |
Why?
|
| Hemizygote | 1 | 2017 | 28 | 0.040 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2003 | 721 | 0.040 |
Why?
|
| Drug Interactions | 2 | 2017 | 1460 | 0.040 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2017 | 33 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2009 | 3476 | 0.040 |
Why?
|
| Standard of Care | 1 | 2022 | 564 | 0.040 |
Why?
|
| Phencyclidine | 1 | 2017 | 61 | 0.040 |
Why?
|
| Histocytochemistry | 2 | 1997 | 719 | 0.040 |
Why?
|
| Dyslexia, Acquired | 1 | 1997 | 14 | 0.040 |
Why?
|
| Shock | 1 | 2020 | 318 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 4933 | 0.040 |
Why?
|
| Quality of Life | 4 | 2023 | 12802 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 2000 | 1420 | 0.040 |
Why?
|
| Cerebellum | 3 | 2013 | 1488 | 0.040 |
Why?
|
| Half-Life | 1 | 1998 | 661 | 0.040 |
Why?
|
| Uterus | 1 | 2002 | 711 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2003 | 2086 | 0.040 |
Why?
|
| Diethylnitrosamine | 1 | 2016 | 38 | 0.040 |
Why?
|
| Ferritins | 2 | 1990 | 590 | 0.040 |
Why?
|
| Chronic Disease | 4 | 2021 | 9145 | 0.040 |
Why?
|
| Language Tests | 1 | 1997 | 202 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2023 | 1005 | 0.040 |
Why?
|
| Trinucleotide Repeats | 1 | 1998 | 261 | 0.040 |
Why?
|
| Haloperidol | 1 | 1978 | 397 | 0.040 |
Why?
|
| Benchmarking | 1 | 2024 | 1042 | 0.040 |
Why?
|
| Body Weight | 3 | 1993 | 4671 | 0.040 |
Why?
|
| Automation | 1 | 2019 | 584 | 0.040 |
Why?
|
| Metals, Rare Earth | 3 | 1995 | 17 | 0.040 |
Why?
|
| Dextrans | 2 | 1996 | 595 | 0.040 |
Why?
|
| Medical Record Linkage | 1 | 2018 | 284 | 0.040 |
Why?
|
| Biopsy | 4 | 2010 | 6755 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2006 | 2251 | 0.040 |
Why?
|
| In Situ Hybridization | 2 | 2007 | 1950 | 0.040 |
Why?
|
| Neurochemistry | 1 | 1996 | 29 | 0.040 |
Why?
|
| Choline | 2 | 1999 | 493 | 0.040 |
Why?
|
| Visual Fields | 3 | 1998 | 1047 | 0.040 |
Why?
|
| Electron Transport Complex II | 1 | 1996 | 48 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2022 | 1119 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2012 | 6542 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2011 | 17446 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 1999 | 936 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2017 | 1157 | 0.030 |
Why?
|
| Forecasting | 3 | 1995 | 2951 | 0.030 |
Why?
|
| Oxidoreductases | 2 | 1996 | 424 | 0.030 |
Why?
|
| Self Report | 2 | 2019 | 3553 | 0.030 |
Why?
|
| Prochlorperazine | 1 | 2015 | 17 | 0.030 |
Why?
|
| Child, Preschool | 5 | 2019 | 41005 | 0.030 |
Why?
|
| Spectrophotometry | 1 | 2016 | 313 | 0.030 |
Why?
|
| Schizophrenic Psychology | 2 | 2013 | 1678 | 0.030 |
Why?
|
| China | 1 | 2022 | 2245 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2004 | 1338 | 0.030 |
Why?
|
| Methamphetamine | 1 | 2017 | 154 | 0.030 |
Why?
|
| Perfusion | 3 | 2002 | 1360 | 0.030 |
Why?
|
| Chloralose | 1 | 2015 | 14 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2016 | 1892 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2018 | 1105 | 0.030 |
Why?
|
| Body Height | 2 | 1993 | 1578 | 0.030 |
Why?
|
| Random Allocation | 2 | 2016 | 2428 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2021 | 2618 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 1997 | 536 | 0.030 |
Why?
|
| Succinate Dehydrogenase | 1 | 1996 | 146 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 550 | 0.030 |
Why?
|
| Oxyhemoglobins | 2 | 2008 | 216 | 0.030 |
Why?
|
| Optical Illusions | 1 | 1995 | 40 | 0.030 |
Why?
|
| DNA | 1 | 2009 | 7294 | 0.030 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2017 | 162 | 0.030 |
Why?
|
| Narcotics | 1 | 1997 | 343 | 0.030 |
Why?
|
| Happiness | 1 | 1996 | 170 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2002 | 3616 | 0.030 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1999 | 703 | 0.030 |
Why?
|
| Hospitals, Psychiatric | 1 | 1976 | 332 | 0.030 |
Why?
|
| Receptors, AMPA | 1 | 1997 | 332 | 0.030 |
Why?
|
| Biogenic Amines | 1 | 1994 | 50 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 856 | 0.030 |
Why?
|
| Diprenorphine | 1 | 2014 | 13 | 0.030 |
Why?
|
| Models, Statistical | 5 | 2007 | 5101 | 0.030 |
Why?
|
| Dyslexia | 1 | 1997 | 248 | 0.030 |
Why?
|
| Nucleus Accumbens | 1 | 1997 | 366 | 0.030 |
Why?
|
| Tyrosine | 2 | 1998 | 1462 | 0.030 |
Why?
|
| Glucosylceramidase | 1 | 1995 | 125 | 0.030 |
Why?
|
| Survival Rate | 3 | 2018 | 12788 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 551 | 0.030 |
Why?
|
| Calibration | 1 | 2017 | 816 | 0.030 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1994 | 87 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2019 | 885 | 0.030 |
Why?
|
| Models, Cardiovascular | 3 | 1997 | 996 | 0.030 |
Why?
|
| Imagination | 1 | 1996 | 221 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 1999 | 950 | 0.030 |
Why?
|
| Azides | 1 | 1994 | 116 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 627 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2018 | 592 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 1999 | 2242 | 0.030 |
Why?
|
| Receptors, Glutamate | 1 | 1995 | 232 | 0.030 |
Why?
|
| Digoxigenin | 1 | 1994 | 26 | 0.030 |
Why?
|
| Linear Models | 3 | 2016 | 5953 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1997 | 566 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 804 | 0.030 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2017 | 200 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 1995 | 216 | 0.030 |
Why?
|
| Quinolinic Acid | 1 | 1994 | 67 | 0.030 |
Why?
|
| Atrophy | 2 | 2012 | 1584 | 0.030 |
Why?
|
| Cisplatin | 2 | 1999 | 1662 | 0.030 |
Why?
|
| Indazoles | 1 | 1995 | 290 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1997 | 1828 | 0.030 |
Why?
|
| Drainage | 1 | 2000 | 1142 | 0.030 |
Why?
|
| Evoked Potentials, Motor | 1 | 1997 | 454 | 0.030 |
Why?
|
| Nerve Endings | 1 | 1994 | 109 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 683 | 0.030 |
Why?
|
| Polystyrenes | 1 | 1994 | 112 | 0.030 |
Why?
|
| Equipment Design | 3 | 2014 | 3582 | 0.030 |
Why?
|
| RNA Splicing | 1 | 1999 | 908 | 0.030 |
Why?
|
| Receptors, Opioid | 1 | 2014 | 155 | 0.030 |
Why?
|
| Tongue | 1 | 1997 | 406 | 0.030 |
Why?
|
| Skull | 1 | 2018 | 814 | 0.030 |
Why?
|
| Metal Nanoparticles | 2 | 2009 | 405 | 0.030 |
Why?
|
| Acetylcholinesterase | 1 | 1994 | 153 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2007 | 3020 | 0.030 |
Why?
|
| Chlorpromazine | 1 | 1973 | 111 | 0.030 |
Why?
|
| Mice, Transgenic | 3 | 2009 | 9735 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1995 | 437 | 0.030 |
Why?
|
| Gene Frequency | 2 | 2000 | 3587 | 0.030 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2016 | 494 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1998 | 525 | 0.030 |
Why?
|
| Apnea | 1 | 1995 | 195 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 1997 | 1865 | 0.030 |
Why?
|
| Skin Tests | 1 | 2015 | 613 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2000 | 1178 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2013 | 380 | 0.030 |
Why?
|
| Oxidative Stress | 4 | 1999 | 3084 | 0.030 |
Why?
|
| Hypotension | 1 | 1999 | 884 | 0.030 |
Why?
|
| Recurrence | 3 | 2013 | 8340 | 0.030 |
Why?
|
| Antipruritics | 1 | 2012 | 30 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 640 | 0.030 |
Why?
|
| Peptides | 1 | 2005 | 4410 | 0.030 |
Why?
|
| Japan | 1 | 1997 | 1360 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 1996 | 574 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2016 | 23404 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2013 | 206 | 0.030 |
Why?
|
| Depressive Disorder, Major | 1 | 2010 | 4639 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2019 | 1487 | 0.030 |
Why?
|
| Molecular Biology | 1 | 1997 | 596 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 553 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2012 | 2029 | 0.030 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1994 | 375 | 0.030 |
Why?
|
| Nerve Fibers | 1 | 2016 | 687 | 0.030 |
Why?
|
| Aorta, Abdominal | 2 | 1993 | 646 | 0.030 |
Why?
|
| Observer Variation | 1 | 1999 | 2593 | 0.030 |
Why?
|
| Niacinamide | 1 | 1994 | 416 | 0.030 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2014 | 282 | 0.030 |
Why?
|
| Multienzyme Complexes | 1 | 1996 | 686 | 0.030 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 1995 | 555 | 0.030 |
Why?
|
| Remission Induction | 3 | 1994 | 2385 | 0.030 |
Why?
|
| Creatinine | 1 | 1998 | 1919 | 0.030 |
Why?
|
| Hydroxylation | 1 | 1992 | 141 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2012 | 200 | 0.030 |
Why?
|
| Myocardial Infarction | 6 | 2008 | 11718 | 0.030 |
Why?
|
| Models, Chemical | 1 | 1994 | 626 | 0.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 1996 | 604 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1997 | 1213 | 0.030 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 417 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2015 | 1107 | 0.030 |
Why?
|
| Antipsychotic Agents | 2 | 2013 | 3057 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2018 | 956 | 0.030 |
Why?
|
| Deuterium Oxide | 1 | 1991 | 34 | 0.030 |
Why?
|
| Contingent Negative Variation | 1 | 2011 | 34 | 0.030 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2005 | 1813 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 2015 | 559 | 0.030 |
Why?
|
| Aortic Aneurysm | 2 | 1987 | 644 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 349 | 0.030 |
Why?
|
| Ketamine | 1 | 2017 | 501 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 1994 | 915 | 0.030 |
Why?
|
| Deuterium | 1 | 1991 | 101 | 0.020 |
Why?
|
| Capillaries | 2 | 2010 | 773 | 0.020 |
Why?
|
| Lipids | 3 | 1995 | 3307 | 0.020 |
Why?
|
| Chelating Agents | 2 | 1995 | 380 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2017 | 1169 | 0.020 |
Why?
|
| Reference Standards | 1 | 2015 | 1025 | 0.020 |
Why?
|
| Microspheres | 1 | 1994 | 777 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 1641 | 0.020 |
Why?
|
| Substance-Related Disorders | 2 | 1998 | 4257 | 0.020 |
Why?
|
| Consensus | 1 | 2020 | 2960 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 1991 | 419 | 0.020 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 12356 | 0.020 |
Why?
|
| Headache | 1 | 1999 | 1226 | 0.020 |
Why?
|
| Rats, Inbred Strains | 5 | 1992 | 2186 | 0.020 |
Why?
|
| Nanotechnology | 2 | 2007 | 710 | 0.020 |
Why?
|
| Social Class | 1 | 2000 | 1997 | 0.020 |
Why?
|
| Mice, Nude | 2 | 2010 | 3689 | 0.020 |
Why?
|
| tau Proteins | 1 | 2021 | 1868 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 1997 | 165 | 0.020 |
Why?
|
| Kinetics | 2 | 2013 | 6476 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2001 | 4851 | 0.020 |
Why?
|
| Psychotherapy | 2 | 1997 | 1642 | 0.020 |
Why?
|
| Risk Factors | 7 | 2013 | 72296 | 0.020 |
Why?
|
| Medial Forebrain Bundle | 1 | 2010 | 45 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2010 | 6313 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 1997 | 957 | 0.020 |
Why?
|
| Insulin | 2 | 2016 | 6582 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1996 | 1958 | 0.020 |
Why?
|
| Clinical Trials as Topic | 3 | 2015 | 7914 | 0.020 |
Why?
|
| Probability | 1 | 2016 | 2506 | 0.020 |
Why?
|
| Social Behavior | 1 | 1997 | 1127 | 0.020 |
Why?
|
| Sympathectomy, Chemical | 2 | 2000 | 22 | 0.020 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1993 | 549 | 0.020 |
Why?
|
| Movement Disorders | 1 | 1994 | 446 | 0.020 |
Why?
|
| BRCA2 Protein | 3 | 2001 | 794 | 0.020 |
Why?
|
| Phosphorothioate Oligonucleotides | 1 | 2009 | 10 | 0.020 |
Why?
|
| Family Health | 1 | 2015 | 1281 | 0.020 |
Why?
|
| Particle Size | 1 | 1994 | 1642 | 0.020 |
Why?
|
| Self Administration | 1 | 2011 | 385 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2014 | 562 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2011 | 270 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 1758 | 0.020 |
Why?
|
| Amenorrhea | 1 | 1993 | 485 | 0.020 |
Why?
|
| Photomicrography | 1 | 2009 | 74 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1995 | 2421 | 0.020 |
Why?
|
| Microscopy, Video | 1 | 2010 | 245 | 0.020 |
Why?
|
| Recombinant Proteins | 3 | 2006 | 6621 | 0.020 |
Why?
|
| Odds Ratio | 3 | 2011 | 9849 | 0.020 |
Why?
|
| Avoidance Learning | 1 | 2010 | 233 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2569 | 0.020 |
Why?
|
| Spectrum Analysis | 2 | 1989 | 454 | 0.020 |
Why?
|
| Radiation Injuries | 2 | 2004 | 1180 | 0.020 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 12244 | 0.020 |
Why?
|
| ROC Curve | 3 | 2004 | 3528 | 0.020 |
Why?
|
| Embolism | 1 | 2012 | 408 | 0.020 |
Why?
|
| Parotid Diseases | 1 | 1989 | 46 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2011 | 595 | 0.020 |
Why?
|
| United States | 4 | 2023 | 69872 | 0.020 |
Why?
|
| Computer Security | 1 | 2011 | 262 | 0.020 |
Why?
|
| Diagnosis, Differential | 4 | 2004 | 12961 | 0.020 |
Why?
|
| Oxidopamine | 2 | 2000 | 169 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2016 | 3914 | 0.020 |
Why?
|
| Dipyridamole | 3 | 1996 | 145 | 0.020 |
Why?
|
| Genotype | 2 | 2015 | 12952 | 0.020 |
Why?
|
| Neuropeptides | 1 | 1994 | 942 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 3086 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2002 | 5984 | 0.020 |
Why?
|
| Fibrosis | 1 | 2015 | 2029 | 0.020 |
Why?
|
| Glutamate Decarboxylase | 1 | 2009 | 245 | 0.020 |
Why?
|
| Substance P | 3 | 1994 | 335 | 0.020 |
Why?
|
| Neoplasms | 2 | 2017 | 21696 | 0.020 |
Why?
|
| Electrocardiography | 5 | 2007 | 6442 | 0.020 |
Why?
|
| Illusions | 1 | 2008 | 60 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 6171 | 0.020 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2012 | 379 | 0.020 |
Why?
|
| Macaca | 2 | 2003 | 440 | 0.020 |
Why?
|
| Affect | 1 | 1996 | 1475 | 0.020 |
Why?
|
| Disease Progression | 3 | 2013 | 13286 | 0.020 |
Why?
|
| Risk Assessment | 4 | 2011 | 23336 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1996 | 2036 | 0.020 |
Why?
|
| Allergens | 1 | 2015 | 1320 | 0.020 |
Why?
|
| Mental Disorders | 2 | 1999 | 6598 | 0.020 |
Why?
|
| Autoradiography | 1 | 2008 | 745 | 0.020 |
Why?
|
| Perception | 2 | 2009 | 1198 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1184 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 2021 | 3587 | 0.020 |
Why?
|
| Afferent Pathways | 1 | 2009 | 302 | 0.020 |
Why?
|
| Methotrexate | 1 | 1994 | 1728 | 0.020 |
Why?
|
| Agar | 1 | 2007 | 56 | 0.020 |
Why?
|
| Somatostatin | 3 | 1994 | 459 | 0.020 |
Why?
|
| Neostriatum | 2 | 2000 | 250 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1978 | 2708 | 0.020 |
Why?
|
| Median Nerve | 1 | 2008 | 129 | 0.020 |
Why?
|
| Arteries | 1 | 1992 | 1119 | 0.020 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2011 | 360 | 0.020 |
Why?
|
| Parotid Neoplasms | 1 | 1989 | 155 | 0.020 |
Why?
|
| Haplorhini | 2 | 2000 | 552 | 0.020 |
Why?
|
| Genes, fos | 1 | 2007 | 183 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 1998 | 2148 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 1993 | 976 | 0.020 |
Why?
|
| Vulvar Neoplasms | 1 | 1989 | 272 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2007 | 242 | 0.020 |
Why?
|
| Research | 1 | 1995 | 1999 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 1988 | 226 | 0.020 |
Why?
|
| Gels | 1 | 2008 | 427 | 0.020 |
Why?
|
| Physical Fitness | 1 | 1991 | 732 | 0.020 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 1995 | 1265 | 0.020 |
Why?
|
| Regression Analysis | 2 | 1993 | 6459 | 0.020 |
Why?
|
| Hindlimb | 1 | 2008 | 504 | 0.020 |
Why?
|
| Cyclic N-Oxides | 2 | 1997 | 78 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2005 | 1572 | 0.020 |
Why?
|
| Fats | 1 | 1986 | 102 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3873 | 0.020 |
Why?
|
| Free Radicals | 2 | 1998 | 237 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 1999 | 5388 | 0.020 |
Why?
|
| Arteriovenous Malformations | 2 | 1987 | 396 | 0.020 |
Why?
|
| Vibration | 1 | 2008 | 326 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2006 | 99 | 0.020 |
Why?
|
| Lymphangioma | 1 | 1986 | 65 | 0.020 |
Why?
|
| Nitrogen Oxides | 2 | 1997 | 129 | 0.020 |
Why?
|
| Salicylamides | 1 | 2005 | 33 | 0.020 |
Why?
|
| Mental Health | 1 | 2000 | 3010 | 0.020 |
Why?
|
| Ethylenediamines | 1 | 1985 | 48 | 0.020 |
Why?
|
| Plasminogen Activators | 1 | 2006 | 209 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 1660 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2008 | 597 | 0.020 |
Why?
|
| Galvanic Skin Response | 1 | 2007 | 349 | 0.020 |
Why?
|
| Coenzymes | 2 | 1997 | 91 | 0.020 |
Why?
|
| Ethionine | 1 | 1985 | 11 | 0.020 |
Why?
|
| Pedigree | 3 | 2000 | 4642 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2011 | 745 | 0.020 |
Why?
|
| beta-Alanine | 1 | 2005 | 74 | 0.020 |
Why?
|
| Lipomatosis | 1 | 1986 | 112 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2009 | 710 | 0.020 |
Why?
|
| Drug Evaluation | 2 | 1978 | 647 | 0.020 |
Why?
|
| Gene Expression | 1 | 2018 | 7798 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2015 | 3203 | 0.020 |
Why?
|
| Iron Chelating Agents | 1 | 1985 | 139 | 0.020 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 2 | 1994 | 64 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 2 | 1999 | 481 | 0.020 |
Why?
|
| NADPH Dehydrogenase | 2 | 1994 | 45 | 0.020 |
Why?
|
| Homovanillic Acid | 2 | 1994 | 75 | 0.020 |
Why?
|
| Carotid Artery, Internal | 1 | 2007 | 445 | 0.020 |
Why?
|
| Laser Therapy | 1 | 1991 | 1072 | 0.020 |
Why?
|
| Internal Capsule | 1 | 2004 | 113 | 0.020 |
Why?
|
| Morbidity | 2 | 2004 | 1768 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1999 | 4245 | 0.010 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2009 | 518 | 0.010 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 1993 | 1186 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 15520 | 0.010 |
Why?
|
| Evoked Potentials, Auditory | 1 | 1987 | 525 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1997 | 4463 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 2088 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 1999 | 3658 | 0.010 |
Why?
|
| Rats, Nude | 1 | 2003 | 105 | 0.010 |
Why?
|
| Intermittent Claudication | 1 | 1986 | 309 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2007 | 2050 | 0.010 |
Why?
|
| Rats, Inbred WKY | 2 | 1993 | 158 | 0.010 |
Why?
|
| Age Distribution | 1 | 2009 | 2902 | 0.010 |
Why?
|
| Systole | 1 | 1985 | 958 | 0.010 |
Why?
|
| Fertility | 1 | 2008 | 781 | 0.010 |
Why?
|
| Diastole | 1 | 1985 | 791 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 2850 | 0.010 |
Why?
|
| Recruitment, Neurophysiological | 1 | 2002 | 32 | 0.010 |
Why?
|
| Length of Stay | 1 | 1976 | 6311 | 0.010 |
Why?
|
| Semantics | 2 | 1998 | 585 | 0.010 |
Why?
|
| Neuropeptide Y | 2 | 1994 | 200 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 1996 | 3229 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6539 | 0.010 |
Why?
|
| Pons | 1 | 1984 | 245 | 0.010 |
Why?
|
| Menopause | 1 | 2011 | 1626 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 1994 | 529 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2015 | 2943 | 0.010 |
Why?
|
| Dental Materials | 1 | 1983 | 108 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2016 | 3864 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4468 | 0.010 |
Why?
|
| Massachusetts | 1 | 2015 | 8662 | 0.010 |
Why?
|
| Heart Neoplasms | 1 | 1986 | 374 | 0.010 |
Why?
|
| Lung | 1 | 2021 | 9857 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 2917 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2009 | 1828 | 0.010 |
Why?
|
| Scopolamine | 1 | 2001 | 99 | 0.010 |
Why?
|
| Demyelinating Diseases | 1 | 1984 | 354 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2012 | 3493 | 0.010 |
Why?
|
| Arm | 1 | 1984 | 589 | 0.010 |
Why?
|
| Risk | 1 | 2013 | 9688 | 0.010 |
Why?
|
| Computers | 1 | 1984 | 612 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2001 | 326 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2009 | 3001 | 0.010 |
Why?
|
| Muscarinic Antagonists | 1 | 2001 | 137 | 0.010 |
Why?
|
| Association Learning | 1 | 2003 | 224 | 0.010 |
Why?
|
| Lorazepam | 1 | 2001 | 145 | 0.010 |
Why?
|
| Parity | 1 | 2004 | 929 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1985 | 1092 | 0.010 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 16690 | 0.010 |
Why?
|
| Heart Septum | 2 | 1996 | 312 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2012 | 2751 | 0.010 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2007 | 964 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1993 | 4397 | 0.010 |
Why?
|
| Sympatholytics | 1 | 2000 | 83 | 0.010 |
Why?
|
| Markov Chains | 1 | 2004 | 969 | 0.010 |
Why?
|
| Olfactory Pathways | 1 | 2001 | 121 | 0.010 |
Why?
|
| Cell Division | 1 | 2008 | 4569 | 0.010 |
Why?
|
| Striatonigral Degeneration | 1 | 1999 | 13 | 0.010 |
Why?
|
| Adenoma | 1 | 1991 | 2174 | 0.010 |
Why?
|
| Incidence | 2 | 2013 | 20952 | 0.010 |
Why?
|
| Stereotyped Behavior | 1 | 2000 | 136 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2015 | 3749 | 0.010 |
Why?
|
| Intracranial Embolism | 1 | 2001 | 202 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 5445 | 0.010 |
Why?
|
| Compliance | 1 | 1999 | 104 | 0.010 |
Why?
|
| Toes | 1 | 2000 | 206 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4751 | 0.010 |
Why?
|
| Necrosis | 1 | 2004 | 1643 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2003 | 931 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 1970 | 0.010 |
Why?
|
| Anti-Anxiety Agents | 1 | 2001 | 390 | 0.010 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2002 | 367 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2006 | 1533 | 0.010 |
Why?
|
| Age Factors | 2 | 2011 | 18373 | 0.010 |
Why?
|
| Metals | 1 | 1983 | 719 | 0.010 |
Why?
|
| Epilepsy | 1 | 1994 | 3310 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 2556 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2018 | 25628 | 0.010 |
Why?
|
| Ethanol | 1 | 1985 | 1342 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1987 | 1161 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3611 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2010 | 3690 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 2971 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1998 | 234 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 2700 | 0.010 |
Why?
|
| Women's Health | 1 | 2007 | 2034 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 2 | 1987 | 1363 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 2006 | 8642 | 0.010 |
Why?
|
| Calcinosis | 1 | 1986 | 1499 | 0.010 |
Why?
|
| Benzazepines | 1 | 2000 | 326 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 5856 | 0.010 |
Why?
|
| Adrenergic Agents | 1 | 1997 | 70 | 0.010 |
Why?
|
| Nonlinear Dynamics | 1 | 2000 | 502 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 1917 | 0.010 |
Why?
|
| Inferior Colliculi | 1 | 1998 | 68 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 1809 | 0.010 |
Why?
|
| Awareness | 1 | 2001 | 640 | 0.010 |
Why?
|
| Fluoroimmunoassay | 1 | 1996 | 33 | 0.010 |
Why?
|
| Volition | 1 | 1997 | 63 | 0.010 |
Why?
|
| Dextroamphetamine | 1 | 1997 | 129 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2007 | 1470 | 0.010 |
Why?
|
| Online Systems | 1 | 1998 | 184 | 0.010 |
Why?
|
| Triglycerides | 1 | 1985 | 2453 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 1998 | 383 | 0.010 |
Why?
|
| Multilingualism | 1 | 1997 | 87 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2006 | 4222 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 35134 | 0.010 |
Why?
|
| Self-Assessment | 1 | 1978 | 390 | 0.010 |
Why?
|
| North America | 1 | 2000 | 1249 | 0.010 |
Why?
|
| Neurotrophin 3 | 1 | 1996 | 59 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 2001 | 12025 | 0.010 |
Why?
|
| Antihypertensive Agents | 2 | 1998 | 2047 | 0.010 |
Why?
|
| Psittacosis | 1 | 1955 | 4 | 0.010 |
Why?
|
| Life Style | 1 | 2007 | 3835 | 0.010 |
Why?
|
| Inflammation | 1 | 2015 | 10637 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2004 | 2307 | 0.010 |
Why?
|
| Truth Disclosure | 1 | 2000 | 436 | 0.010 |
Why?
|
| Ischemia | 1 | 1984 | 1907 | 0.010 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 1995 | 70 | 0.010 |
Why?
|
| Venules | 1 | 1995 | 165 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1983 | 1387 | 0.010 |
Why?
|
| Hydroxyl Radical | 1 | 1995 | 78 | 0.010 |
Why?
|
| Postoperative Complications | 2 | 1993 | 15297 | 0.010 |
Why?
|
| Kidney | 1 | 1991 | 7184 | 0.010 |
Why?
|
| Sodium Azide | 1 | 1994 | 24 | 0.010 |
Why?
|
| Coronary Disease | 2 | 1987 | 6077 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 9647 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 10483 | 0.010 |
Why?
|
| Kainic Acid | 1 | 1995 | 199 | 0.010 |
Why?
|
| Hyperemia | 1 | 1996 | 225 | 0.010 |
Why?
|
| Quality Control | 1 | 1998 | 841 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 1997 | 458 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 9384 | 0.010 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 1994 | 73 | 0.010 |
Why?
|
| Lod Score | 1 | 1995 | 614 | 0.010 |
Why?
|
| DNA Primers | 1 | 1999 | 2891 | 0.010 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 1993 | 59 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1991 | 4262 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1999 | 1771 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1994 | 425 | 0.010 |
Why?
|
| Laboratories | 1 | 1998 | 463 | 0.010 |
Why?
|
| Glycolysis | 1 | 1998 | 829 | 0.010 |
Why?
|
| Microinjections | 1 | 1994 | 327 | 0.010 |
Why?
|
| Contrast Sensitivity | 1 | 1995 | 244 | 0.010 |
Why?
|
| Affective Symptoms | 1 | 1976 | 407 | 0.010 |
Why?
|
| Electrodes | 1 | 1996 | 619 | 0.010 |
Why?
|
| Eye Movements | 1 | 1997 | 507 | 0.010 |
Why?
|
| Psychoacoustics | 1 | 1993 | 57 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1991 | 12721 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2001 | 1002 | 0.010 |
Why?
|
| Macrophages | 1 | 2008 | 5660 | 0.010 |
Why?
|
| Thrombosis | 1 | 1987 | 2968 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 7282 | 0.010 |
Why?
|
| Psychotherapy, Group | 1 | 1976 | 406 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 12262 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1985 | 5006 | 0.010 |
Why?
|
| Leucovorin | 1 | 1994 | 628 | 0.010 |
Why?
|
| Isoquinolines | 1 | 1994 | 366 | 0.010 |
Why?
|
| Extremities | 1 | 1998 | 866 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 1994 | 476 | 0.010 |
Why?
|
| Electrochemistry | 1 | 1992 | 145 | 0.010 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 1993 | 266 | 0.010 |
Why?
|
| Employment | 1 | 1978 | 1132 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1996 | 976 | 0.010 |
Why?
|
| Auditory Threshold | 1 | 1993 | 364 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1995 | 1151 | 0.010 |
Why?
|
| Cadaver | 1 | 1995 | 1337 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1999 | 1403 | 0.010 |
Why?
|
| Aorta | 2 | 1992 | 2062 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 4185 | 0.010 |
Why?
|
| Bone Density | 2 | 1995 | 3468 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 12073 | 0.010 |
Why?
|
| Apoptosis | 1 | 2007 | 9724 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2004 | 2213 | 0.010 |
Why?
|
| Urban Population | 1 | 1978 | 2022 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1996 | 2726 | 0.010 |
Why?
|
| Alleles | 1 | 2001 | 6933 | 0.010 |
Why?
|
| Coronary Vessels | 2 | 1996 | 3107 | 0.010 |
Why?
|
| Mitomycins | 1 | 1989 | 47 | 0.010 |
Why?
|
| Canada | 1 | 1995 | 2065 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 1995 | 1686 | 0.010 |
Why?
|
| Cell Death | 1 | 1995 | 1707 | 0.010 |
Why?
|
| Cricetinae | 1 | 1993 | 2475 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 1992 | 440 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 13409 | 0.010 |
Why?
|
| Osteoradionecrosis | 1 | 1989 | 49 | 0.010 |
Why?
|
| Mitomycin | 1 | 1989 | 259 | 0.010 |
Why?
|
| Interneurons | 1 | 1993 | 577 | 0.010 |
Why?
|
| Homeostasis | 1 | 1999 | 3339 | 0.010 |
Why?
|
| Plasmacytoma | 1 | 1989 | 183 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1993 | 1074 | 0.000 |
Why?
|
| Gynecology | 1 | 1993 | 513 | 0.000 |
Why?
|
| Minerals | 1 | 1989 | 275 | 0.000 |
Why?
|
| Base Sequence | 1 | 1999 | 12797 | 0.000 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1993 | 1504 | 0.000 |
Why?
|
| Occupational Diseases | 1 | 1955 | 1469 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1995 | 4740 | 0.000 |
Why?
|
| Melanoma | 3 | 1995 | 5511 | 0.000 |
Why?
|
| Spleen | 1 | 1992 | 2362 | 0.000 |
Why?
|
| Audiometry, Pure-Tone | 1 | 1987 | 204 | 0.000 |
Why?
|
| Densitometry | 1 | 1986 | 156 | 0.000 |
Why?
|
| Erythrocytes | 1 | 1995 | 2455 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1990 | 1101 | 0.000 |
Why?
|
| Sodium Pertechnetate Tc 99m | 1 | 1985 | 57 | 0.000 |
Why?
|
| Leukemia, Lymphoid | 1 | 1985 | 315 | 0.000 |
Why?
|
| Constriction | 1 | 1985 | 181 | 0.000 |
Why?
|
| Fluorouracil | 1 | 1989 | 1619 | 0.000 |
Why?
|
| Data Display | 1 | 1985 | 182 | 0.000 |
Why?
|
| Aortography | 1 | 1986 | 437 | 0.000 |
Why?
|
| Spinal Diseases | 1 | 1989 | 538 | 0.000 |
Why?
|
| Hypertrophy | 1 | 1986 | 569 | 0.000 |
Why?
|
| Endocardium | 1 | 1985 | 263 | 0.000 |
Why?
|
| Pericardial Effusion | 1 | 1985 | 247 | 0.000 |
Why?
|
| Giant Cell Tumors | 1 | 1983 | 99 | 0.000 |
Why?
|
| Radiotherapy Dosage | 1 | 1989 | 2879 | 0.000 |
Why?
|
| Tibial Fractures | 1 | 1985 | 269 | 0.000 |
Why?
|
| Hemostasis, Surgical | 1 | 1983 | 128 | 0.000 |
Why?
|
| Thorax | 1 | 1985 | 547 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1994 | 5096 | 0.000 |
Why?
|
| Medical Oncology | 1 | 1993 | 2267 | 0.000 |
Why?
|
| Neck | 1 | 1986 | 698 | 0.000 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1976 | 3537 | 0.000 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1986 | 934 | 0.000 |
Why?
|
| Pericardium | 1 | 1985 | 667 | 0.000 |
Why?
|
| Aorta, Thoracic | 1 | 1987 | 1084 | 0.000 |
Why?
|
| Heart Atria | 1 | 1986 | 1356 | 0.000 |
Why?
|
| Aneurysm | 1 | 1983 | 339 | 0.000 |
Why?
|
| Hematoma | 1 | 1984 | 758 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1995 | 19233 | 0.000 |
Why?
|
| Osteosarcoma | 1 | 1983 | 881 | 0.000 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1984 | 1018 | 0.000 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1991 | 3143 | 0.000 |
Why?
|
| Cardiomyopathies | 1 | 1985 | 1912 | 0.000 |
Why?
|
| Pregnancy | 1 | 1994 | 29144 | 0.000 |
Why?
|
| Heart Defects, Congenital | 1 | 1985 | 4583 | 0.000 |
Why?
|
| Heart Valve Prosthesis | 1 | 1976 | 1490 | 0.000 |
Why?
|
| Coronary Artery Bypass | 1 | 1976 | 2288 | 0.000 |
Why?
|
| Suicide | 1 | 1976 | 1474 | 0.000 |
Why?
|
| Delirium | 1 | 1976 | 1610 | 0.000 |
Why?
|
| Hospitalization | 1 | 1976 | 10259 | 0.000 |
Why?
|